Sort
48,018 grants matching “immunotherapy”
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$620,991Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2021 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$620,943Rebecca L Aft · Washington University · R01 · FY2024 · CA
Toward translation of a plant virus-based in situ vaccination nanotechnology
$620,922Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2025 · CA
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
$620,882Sophia S. Wang · Beckman Research Institute/City Of Hope · R01 · FY2014 · CA
Investigating CREB5-driven mechanisms of immune therapy resistance
$620,820Robert Thomas Manguso · Massachusetts General Hospital · R01 · FY2025 · CA
INTEGRATING TUMOR GENETICS AND MICROENVIRONMENT AS PREDICTORS OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY IN OVARIAN CANCER
$620,791Trustees Of The University Of Pennsylvania, The · · FY2021 · Defense Health Agency
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$620,740Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2023 · CA
T Cell Memory to Viruses
$620,693Rafi Ahmed · Emory University · R01 · FY2024 · AI
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$620,673Miguel Angel Villalona · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
$620,672Sandra P D'angelo · Sloan-Kettering Inst Can Research · R01 · FY2024 · FD
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis
$620,640Andrea Schietinger · Sloan-Kettering Inst Can Research · U54 · FY2018 · CA
GM-CSF, macrophages, and susceptibility to Mycobacterium abscessus pulmonary infection
$620,636Katherine B Hisert · National Jewish Health · R01 · FY2025 · HL
MODELING NEOANTIGEN AND TCR DYNAMICS IN MELANOMA AND ITS ROLE IN ACQUIRED RESISTANCE TO IMMUNOTHERAPY USING AUTOLOGOUS THYMUS-BEARING HUMANIZED MICE
$620,599The Regents Of The University Of Colorado · · FY2018 · Department of the Army
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$620,514Harry H Yoon · Mayo Clinic Rochester · R01 · FY2023 · CA
Host-Directed Immunotherapy: A "One Health" Approach
$620,473Joseph Anthoney Vetro · University Of Nebraska Medical Center · R01 · FY2020 · AI
Defining the role of cytomegalovirus in glioblastoma therapies
$620,471Sean Edward Lawler · Brown University · R01 · FY2024 · CA
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$620,466Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2024 · CA
Blocking the binding of Aβ and apoE as a novel therapeutic approach for AD
$620,426Thomas M Wisniewski · New York University School Of Medicine · P01 · FY2022 · AG
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
$620,343Xiaobo Mao · Johns Hopkins University · R01 · FY2025 · AG
Regulatory dendritic cell therapy, promotion of tolerance and underlying mechanisms in NHP renal transplantation
$620,325Angus W Thomson · University Of Pittsburgh At Pittsburgh · U19 · FY2021 · AI
Regulatory dendritic cell therapy, promotion of tolerance and underlying mechanisms in NHP renal transplantation
$620,325Angus W Thomson · University Of Pittsburgh At Pittsburgh · U19 · FY2020 · AI
RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
$620,284University Of Michigan At Ann Arbor · U01 · FY2001 · DK
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
$620,252John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · CA
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
$620,234Michael T Lewis · Baylor College Of Medicine · U24 · FY2022 · CA
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
$620,231Michael T Lewis · Baylor College Of Medicine · U24 · FY2023 · CA